Evaluation of eight lateral flow tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population

Greenland-Bews, Caitlin and Byrne, Rachel L. and Owen, Sophie I. and Watkins, Rachel L. and Bengey, Daisy and Buist, Kate and Clerkin, Karina and Escadafal, Camille and Finch, Lorna S. and Gould, Susan and Giorgi, Emanuele and Hodgkinson, Andy and Mashenko, Larysa and Powell, Darren and Savage, Helen R. and Thompson, Caitlin R. and Turtle, Lance and Wardale, Jahanara and Wooding, Dominic and Edwards, Thomas and Atienzar, Ana Cubas and Adams, Emily R. (2023) Evaluation of eight lateral flow tests for the detection of anti-SARS-CoV-2 antibodies in a vaccinated population. BMC Infectious Diseases, 23 (1). pp. 1-7. ISSN 1471-2334

Full text not available from this repository.


Background: Rapid determination of an individual’s antibody status can be beneficial in understanding an individual’s immune response to SARS-CoV-2 and for initiation of therapies that are only deemed effective in sero-negative individuals. Antibody lateral flow tests (LFTs) have potential to address this need as a rapid, point of care test. Methods: Here we present a proof-of-concept evaluation of eight LFT brands using sera from 95 vaccinated individuals to determine sensitivity for detecting vaccination generated antibodies. Samples were analysed on eight different brands of antibody LFT and an automated chemiluminescent microparticle immunoassay (CMIA) that identifies anti-spike antibodies which was used as our reference standard. Results: All 95 (100%) participants tested positive for anti-spike antibodies by the chemiluminescent microparticle immunoassay (CMIA) reference standard post-dose two of their SARS-CoV-2 vaccine: BNT162b2 (Pfizer/BioNTech, n = 60), AZD1222 (AstraZeneca, n = 31), mRNA-1273 (Moderna, n = 2) and Undeclared Vaccine Brand (n = 2). Sensitivity increased from dose one to dose two in six out of eight LFTs with three tests achieving 100% sensitivity at dose two in detecting anti-spike antibodies. Conclusions: These tests are demonstrated to be highly sensitive to detect raised antibody levels in vaccinated individuals. RDTs are low cost and rapid alternatives to ELISA based systems.

Item Type:
Journal Article
Journal or Publication Title:
BMC Infectious Diseases
Uncontrolled Keywords:
ID Code:
Deposited By:
Deposited On:
24 Feb 2023 10:25
Last Modified:
15 Sep 2023 04:43